Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

2023146 citationsJournal Articlegreen Open Access

Authors

Shawn G. Kwatra · Johns Hopkins University

Gil Yosipovitch · Johns Hopkins University

Franz J. Legat · Johns Hopkins University

Adam Reich · Johns Hopkins University

C. Paul · Johns Hopkins University

Dagmar Simon · Johns Hopkins University

Luigi Naldi ·

Abstract

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).

Topics & Keywords

Dermatology and Skin Diseases Medicine and Dermatology Studies History Urticaria and Related Conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 389, Issue 17, pp. 1579-1589

DOI: 10.1056/nejmoa2301333

Field-Weighted Citation Impact: 41.66